Latest / Pharmacy Podcast Network / Theory & Insights, the Impact of Articificial Intelligence & Large Language Models on Pharma | Executive Dose
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:30Speaker 2: Welcome to Executive Dose, the podcast where pharmaceutical leadership meets
- 0:36Speaker 2: unfiltered insight. Hosted by Stephen Beckman, CEO of Your All Pharma.
- 0:41Speaker 2: Each episode explores the complex forces shaping today's pharmaceutical industry,
- 0:45Speaker 2: from global supply chain stress and regulatory shakeups to innovation
- 0:49Speaker 2: in branded and generic drug markets. Join us as we
- 0:52Speaker 2: engage sea level leaders and decision makers in candid conversations
- 0:56Speaker 2: about navigating disruption, driving growth, and preparing for the next
- 1:00Speaker 2: era of pharmaceutical transformation. Curiosity leads, strategy follows. This is
- 1:05Speaker 2: the Executive Dose.
- 1:10Speaker 3: Hey, welcome back to the Executive Dose. This podcast is
- 1:13Speaker 3: dedicated to the pharmaceutical and pharmacy care markets. I'm so
- 1:18Speaker 3: excited to have the Executive Dose as part of the
- 1:22Speaker 3: Pharmacy Podcast Network. My name is Todd Yuriy, founder of
- 1:25Speaker 3: the Pharmacy Podcast, and I met a very special man.
- 1:29Speaker 4: In my life.
- 1:30Speaker 3: I nicknamed him the.
- 1:32Speaker 5: Digital health Godfather.
- 1:33Speaker 3: This is probably ten years ago through a very special
- 1:37Speaker 3: mutual friend, Gilbash of Finn Partners, and I learned all
- 1:41Speaker 3: about what John is doing on a global scale. Recognized
- 1:45Speaker 3: as a thinker, the founder of Nosta Lab and innovation
- 1:49Speaker 3: think tank at the intersection of technology, science and medicine,
- 1:53Speaker 3: he's a leading voice in the convergence of technology and
- 1:57Speaker 3: humanity and he's ranked among the top global in influencers
- 2:01Speaker 3: in innovation and AI and is celebrated for his ability
- 2:04Speaker 3: to analyze emerging trends and ignite transformative dialogue. And I
- 2:09Speaker 3: want to welcome to the stage and to the Executive
- 2:13Speaker 3: Dose John Nosta.
- 2:17Speaker 5: Well, good, good day everybody. You know, Todd, your intros
- 2:20Speaker 5: are becoming loftier and loftier, so I don't know if
- 2:23Speaker 5: I can live up to that.
- 2:25Speaker 3: And our host Steve Beckman, it's good to have you
- 2:28Speaker 3: in the studio, Steve, and I want you to take
- 2:30Speaker 3: it away all right.
- 2:30Speaker 6: Well, Todd, it's a pleasure to be here always. This
- 2:33Speaker 6: is our second formal podcast for Executive Dose, and we
- 2:38Speaker 6: couldn't think of a better topic than about the impact
- 2:41Speaker 6: of AI globally and then hopefully a little bit in
- 2:46Speaker 6: terms of how let me see it impacting us in
- 2:49Speaker 6: the healthcare industry. And John, it is a true pleasure
- 2:53Speaker 6: to have you so with that, why don't we just
- 2:56Speaker 6: start off with probably thirty thousand foot view and you know,
- 3:00Speaker 6: talk about the philosophy and some of the other kind
- 3:03Speaker 6: of elements before we get into anything specific that might
- 3:07Speaker 6: impact us within the healthcare channel.
- 3:10Speaker 5: Well, it's a pleasure to be here there. There's so
- 3:13Speaker 5: many interesting things going on, perhaps not the least of
- 3:18Speaker 5: which is the very essence of speed. It seems to
- 3:21Speaker 5: me that things are changing so quickly that it's hard
- 3:24Speaker 5: for us to kind of plot a strategy when you
- 3:27Speaker 5: don't have an endpoint in mind. We're seeing changes in
- 3:31Speaker 5: in AI and large language models that are changing workflow,
- 3:36Speaker 5: changing dynamics, but also in a strange way, even questioning
- 3:40Speaker 5: the viability of the human construct. You know what, what's
- 3:44Speaker 5: our job? What what do I do? What's the utility
- 3:47Speaker 5: of of my brain? And I think these are these
- 3:49Speaker 5: are big important questions as AI becomes functionally smarter. And
- 3:57Speaker 5: I you know, I'm going to put the put that
- 3:59Speaker 5: in quotes because I've argued that maybe AI should be
- 4:05Speaker 5: better discussed in the context of anti intelligence. Now we
- 4:11Speaker 5: can talk more about that. I'm gonna stop at that
- 4:14Speaker 5: point because that's a very curious notion because I do
- 4:18Speaker 5: believe that AI, in its brilliance, is antithetical to the
- 4:23Speaker 5: human construct of thought. We always often talk about the
- 4:26Speaker 5: Turing test, talk about how AI is getting more and
- 4:29Speaker 5: more and more and more and more like us. But
- 4:33Speaker 5: I believe that it's fundamentally different. We can dig down
- 4:38Speaker 5: into that if you want a little bit, but I
- 4:40Speaker 5: just want to go I just want to jump up
- 4:41Speaker 5: really to that thirty thousand foot level. And here's the idea.
- 4:44Speaker 5: Here's the fundamental idea that I think that it seems
- 4:47Speaker 5: to resonate with crowds around the world, from industry to industry,
- 4:51Speaker 5: and this is it. Gutenberg did something really interesting. He
- 4:55Speaker 5: unlocked words by creating a book. Just think about what
- 4:58Speaker 5: that did. That gave people the opportunity to share knowledge,
- 5:03Speaker 5: to principally read the Bible in Gutenberg's case. But the
- 5:08Speaker 5: interesting twist on that was that he created something for
- 5:11Speaker 5: an audience that was largely illiterate, so that was problematic
- 5:15Speaker 5: and took two hundred years for that to really gain traction. Nevertheless,
- 5:19Speaker 5: Gutenberg unlocked words and that was a pivotal moment in
- 5:23Speaker 5: human history that a few hundred years later we kind
- 5:26Speaker 5: of stumble into this thing called the Internet and the
- 5:29Speaker 5: Internet and principally Google in this context, and what they
- 5:32Speaker 5: did is they unlocked facts. By unlocking facts, what I
- 5:38Speaker 5: mean by that is that it was a sort of
- 5:42Speaker 5: cold transactional engagement. So I asked, how much does an
- 5:49Speaker 5: electron way? Or what's the speed of such and such,
- 5:53Speaker 5: or what's the mean corpuscular volume of a red blood cell?
- 5:57Speaker 5: And I got maybe an answer, might have gotten a link,
- 6:01Speaker 5: and then I have to dig through the link. It
- 6:02Speaker 5: wasn't the most enjoyable procedure, and that reflects to medicine. Also,
- 6:08Speaker 5: we're the early days of the electronic health record, and
- 6:11Speaker 5: the engagement with technology was one of of a cognitive
- 6:14Speaker 5: cumbrance and intellectual incumbrance. So here we have unlocked words
- 6:18Speaker 5: with Gutenberg, we unlock facts in a kind of cold
- 6:22Speaker 5: transational way with Google. And where we are today, I
- 6:25Speaker 5: think is really a fundamental change. And this is what
- 6:28Speaker 5: makes things different. AI principally, large language models unlock thought
- 6:36Speaker 5: and that is a unique dynamic because not only is
- 6:40Speaker 5: it an iterative dynamic or an iterative engage where we
- 6:45Speaker 5: talk speak chat with a large language models, but it
- 6:49Speaker 5: chats back with us in a way that advances our thinking.
- 6:53Speaker 5: The net net is I believe that large language models
- 6:56Speaker 5: make us smarter, even though there's available data through MIT
- 7:01Speaker 5: and Apple that suggests that there's a degree of cognitive
- 7:04Speaker 5: atrophy that we get lazy because we let AI do
- 7:07Speaker 5: all the work. So I'm going to take a breath
- 7:10Speaker 5: and stop there. I think there's lots to one pack,
- 7:12Speaker 5: and we can dig a little deeper into medicine and formula.
- 7:15Speaker 6: Well, John, first of all, I think that really was
- 7:17Speaker 6: a great little history when I think about and putting
- 7:21Speaker 6: them in single words. So we went from words to facts,
- 7:24Speaker 6: the thoughts right, and progrrection, which I think really kind
- 7:27Speaker 6: of puts it in perspective for me. And now we're
- 7:32Speaker 6: translating into that thinking kind of construct. So for me
- 7:37Speaker 6: to two areas that I think would be interesting for
- 7:39Speaker 6: you to kind of expand upon a little bit is
- 7:42Speaker 6: One is workflow, So how does this change workflow in general?
- 7:46Speaker 6: And then maybe specifically we have some examples that within
- 7:50Speaker 6: within healthcare that would be one. And then second, I
- 7:53Speaker 6: like to go back to your point about the human
- 7:56Speaker 6: job or the human role going forward, because I think
- 7:59Speaker 6: that's what scares a lot lot of people. You know,
- 8:01Speaker 6: I'm a professional photographer, and a lot of my experience
- 8:04Speaker 6: with AI is what I can do with some of
- 8:06Speaker 6: my editing, and it's amazing what you can do.
- 8:09Speaker 4: But then you're in.
- 8:10Speaker 6: That constant flux of are we moving away from being
- 8:13Speaker 6: a true photographer and taking the picture correctly up front
- 8:16Speaker 6: versus relying on something back? And then does do we
- 8:20Speaker 6: lose that critical thinking or that situational intelligence? And maybe
- 8:25Speaker 6: how that situational intelligence is really where we still have
- 8:29Speaker 6: a role to play. But maybe you start with workflow.
- 8:32Speaker 6: What's your kind of thoughts on that as you've kind
- 8:34Speaker 6: of thought through all this.
- 8:37Speaker 5: Well, you touched the third rail when you're mentioning some
- 8:41Speaker 5: of the things, So let's take a step back. My
- 8:48Speaker 5: fundamental premp now look even more fundamental than that is
- 8:52Speaker 5: the idea of obsolescence. I think, abstractly, that's what you
- 8:55Speaker 5: were alluding to. You were alluding to this idea of
- 8:58Speaker 5: well why do I take a picture when I have
- 9:01Speaker 5: AI who can do that? And that's that is part
- 9:04Speaker 5: and parcel of the innovative dynamic. In other words, as
- 9:08Speaker 5: our phone becomes obsolete, we get a new one, as
- 9:12Speaker 5: our washing machine, as our car, whatever it may be.
- 9:14Speaker 5: Obsolescence is the flip side to the duality of innovation.
- 9:19Speaker 5: Our our one point five Tesla magnet CT scanner in
- 9:22Speaker 5: the hospital is no longer up to snuff to getting
- 9:25Speaker 5: those crisp high resolution images, so we get a new
- 9:29Speaker 5: one and and that that's kind of the world we
- 9:32Speaker 5: live in. But for the first time, for the first time,
- 9:36Speaker 5: we're actually seeing human cognition on the obsolescence chopping block.
- 9:40Speaker 5: And I think that's that's really at the heart of
- 9:43Speaker 5: I think this sort of maybe it's paranoia, maybe it's
- 9:46Speaker 5: just this this existential reality. Now, now that being said,
- 9:50Speaker 5: let's flip that on its head and and and talk
- 9:54Speaker 5: about photography, because obviously you have an interest in photography.
- 9:58Speaker 5: Let's talk what is the name Matthew Brady? Who's the
- 10:00Speaker 5: guy who did the civil All right, so what the
- 10:03Speaker 5: hell happened to Matthew Brady? Did portraiture go away? Did
- 10:09Speaker 5: photography steal the paint brush from the painter? The answer
- 10:14Speaker 5: is no. And this I think is at the heart
- 10:17Speaker 5: of the dynamic, which is very very important. That is
- 10:21Speaker 5: that the pie does not get into small cut into
- 10:24Speaker 5: smaller pieces. The circle of innovation expands. A couple other
- 10:29Speaker 5: interesting examples aside from look did Matthew Brady ever think
- 10:33Speaker 5: of a selfie? There are there are a couple pictures
- 10:37Speaker 5: that suggest the early day of the selfie. But the
- 10:39Speaker 5: selfie is a billion dollar industry.
- 10:40Speaker 6: That is, I mean he created set up some pictures,
- 10:43Speaker 6: but historically, but we read but that.
- 10:47Speaker 5: I think that's that's what's so interesting to me is
- 10:49Speaker 5: that is that we have to look at the expansive
- 10:53Speaker 5: and expanding nature of innovation and technology. Another another classic
- 10:57Speaker 5: example of that is IBM's Deep Lou And I guess
- 11:01Speaker 5: I think it was Boris Spassky. Was he the guy
- 11:04Speaker 5: who played Deep Blue? So he lost? Right? He lost
- 11:07Speaker 5: to Deep Blue? What about Ken Jennings? How Ken Jennings
- 11:11Speaker 5: on IBM. Watson on Jeopardy was crushed, right lost? Yet
- 11:18Speaker 5: what happened to Ken Jennings? Was he on the ash
- 11:21Speaker 5: heap of history? No, he's the host of the show
- 11:23Speaker 5: that has never been more popular. What about chess? Chess
- 11:28Speaker 5: in the Human Construct has been crushed. No human, including
- 11:32Speaker 5: Magnus the number one player, can be AI. Yet it's
- 11:36Speaker 5: never been more popular. So I think we have to
- 11:39Speaker 5: take a step back and think about the expanding opportunities
- 11:45Speaker 5: the human opportunities to see what we've never seen and
- 11:49Speaker 5: to explore what we've never explored. So again, that comes
- 11:51Speaker 5: from a techno optimist, but I think it's fairly legitimate.
- 11:54Speaker 5: Now we can dig deeper into workflow and that kind
- 11:58Speaker 5: of dynamic. But does that make any sense?
- 12:00Speaker 4: John, I think that's brilliant. Again.
- 12:02Speaker 6: I think what's really nice about this conversation so far
- 12:05Speaker 6: is that we can put a very difficult or maybe
- 12:08Speaker 6: scary situation for a lot of people into some very
- 12:11Speaker 6: simple words. And the thing that really struck me in
- 12:13Speaker 6: that last bit that you were talking about is the
- 12:16Speaker 6: word expansion. And so you know, when we think about
- 12:20Speaker 6: how we apply it to what we do in our
- 12:23Speaker 6: in our in our industry, or in our own personal lives,
- 12:26Speaker 6: is how do we then understand how to look at
- 12:29Speaker 6: that in that context? How do we look at expansion
- 12:32Speaker 6: so we see it as something that can be positive,
- 12:35Speaker 6: something that can be used I mean people, I mean
- 12:39Speaker 6: certain jobs will eventually evolve away because of it. I
- 12:42Speaker 6: think that's what you hear a lot on the internet now.
- 12:45Speaker 6: But you know, one of the examples I think in
- 12:48Speaker 6: our industry that's very interesting is drug discovery. Right, you know,
- 12:52Speaker 6: we use data aggregators a lot before AI is really
- 12:56Speaker 6: taken hold to try to identify these opportunities, because historically
- 13:00Speaker 6: we would have to identify ten thousand opportunities to find
- 13:04Speaker 6: one or two that could potentially be brought forward in development.
- 13:07Speaker 6: So AI in drug discovery or drug acceleration be something
- 13:12Speaker 6: that would help us be even that much more effective.
- 13:14Speaker 6: And that's important because the cost of developing drugs is
- 13:18Speaker 6: so significant and I don't think the normal person really
- 13:21Speaker 6: understands the capital investment that's taken and the risk becauseizations
- 13:25Speaker 6: are developing products, but they still have hurdles overcome, like
- 13:29Speaker 6: FDA approval, So it's a high risk profile. So if
- 13:33Speaker 6: we can think of it in a way that we
- 13:34Speaker 6: can expand how we do that in order to be
- 13:36Speaker 6: even more effective, then that should translate into things like
- 13:40Speaker 6: better drug selection and identification, our ability to potentially build
- 13:47Speaker 6: better clinical programs, and that will make the regulatory process,
- 13:50Speaker 6: approval process even that more successful, not only to the
- 13:53Speaker 6: company but through the FDA and then ultimately to the
- 13:56Speaker 6: benefit of the patient. Any thoughts on that, and.
- 14:00Speaker 5: Well, I think that that you are one hundred percent correct,
- 14:04Speaker 5: But in another way, I would I would posit it
- 14:09Speaker 5: differently then when we look at when we look at
- 14:12Speaker 5: drug development, when we look at chemical screening, when we
- 14:15Speaker 5: look at the whole notion of clinical trials, what we're
- 14:18Speaker 5: doing is we're imposing AI into a clinical construct. We're
- 14:23Speaker 5: taking an old method, taking an old beat up car
- 14:27Speaker 5: that doesn't work real well, and we're well, let's change
- 14:30Speaker 5: the tires or let's change the driver. I say, we
- 14:32Speaker 5: throw away the car. I think fundamentally what we'll be
- 14:35Speaker 5: seeing in drug development is not only unique chemical screening.
- 14:40Speaker 5: It won't even be I don't think it's going to
- 14:42Speaker 5: be screening. I think we're going to have you know,
- 14:44Speaker 5: molecular composition. We're going to look at proteins with with
- 14:47Speaker 5: alpha fold. We're going to actually craft these molecules, and
- 14:50Speaker 5: they're going to be tested in an extraordinary new in
- 14:53Speaker 5: vitro dynamic that's not in vitro but in silico. That
- 14:56Speaker 5: I think that we'll be able to see models that
- 14:58Speaker 5: can test these drugs. And and that is what I think
- 15:05Speaker 5: is the expanding circle.
- 15:06Speaker 6: Well, let me do jumping real quick, because I with you,
- 15:10Speaker 6: because I'm a big believer that we have to do
- 15:12Speaker 6: things different. And you know, the old construct of phase one,
- 15:17Speaker 6: Phase two, Phase three is probably outdated in many ways
- 15:21Speaker 6: with the use of AI and that will again help
- 15:24Speaker 6: do the things that we want to do better.
- 15:27Speaker 5: And yes, I think that that that that we have
- 15:32Speaker 5: to think differently. But here here's an interesting concept. And
- 15:35Speaker 5: then again this is me being the philosopher. I would
- 15:39Speaker 5: say that our brains are extraordinarily optimized yet underperforming underutilized. Now,
- 15:47Speaker 5: now that's not if only we could use one hundred
- 15:49Speaker 5: percent of our brain instead of ten percent, that's not
- 15:51Speaker 5: That's not what I'm talking about here. I'm talking about
- 15:53Speaker 5: the unique aspects of our brain physiologically, the amount of energy,
- 15:56Speaker 5: the amount of blood flow that comes to our brain,
- 15:58Speaker 5: and this unique thing in our in our lower skull
- 16:01Speaker 5: called the circle of Willis that connects the left and
- 16:04Speaker 5: right corotid with the vertebral artery. That is a safety
- 16:09Speaker 5: mechanism that if we lose blood flow in one it
- 16:12Speaker 5: actually fills retro fills into our brain, protecting our brain.
- 16:16Speaker 5: But here's something that I think is really interesting. I
- 16:18Speaker 5: don't think people get this, and I get in trouble.
- 16:22Speaker 5: Todd has heard me say this a few times. But
- 16:25Speaker 5: I believe that our brains are functionally infatigable. Now, let
- 16:29Speaker 5: me take a step back and explain what that means.
- 16:33Speaker 5: If you sprint, your legs hurt, we all know that
- 16:36Speaker 5: that's the build up of lactic acid, and lactic acid
- 16:40Speaker 5: inhibits or impedes function. Right. I can't do one hundred
- 16:44Speaker 5: yard dash and keep going for a mile. I'm not
- 16:47Speaker 5: built that way. But my brain does not have the
- 16:50Speaker 5: capacity for fatigue in the traditional in the traditional way
- 16:56Speaker 5: that muscles fatigue through lactic acid. And that is a
- 17:01Speaker 5: very interesting construct. Let me kind of develop that just
- 17:04Speaker 5: a little bit more. If you've ever been in a
- 17:07Speaker 5: new relationship or a new business venture, or something exciting,
- 17:11Speaker 5: perhaps cognitively intoxicating, if you will, and you're on the
- 17:15Speaker 5: phone for one or two or three hours, it's almost
- 17:18Speaker 5: like some of the new podcasts that go on the
- 17:21Speaker 5: long form podcast that go on for two and three
- 17:24Speaker 5: and four hours, and they are vigorous and they are dynamic,
- 17:27Speaker 5: and they go on and on and on, kind of
- 17:29Speaker 5: in the way I'm going on right now. But at
- 17:31Speaker 5: the end of that podcast, at the end of that
- 17:33Speaker 5: telephone call after three hours, are you tired, are you fatigued?
- 17:38Speaker 5: Do you have that same lactic acid mediated lethargy. No,
- 17:42Speaker 5: and don't confuse that with boredom. It's a very very
- 17:45Speaker 5: different dynamic. We are extraordinarily enthused, energized. At the end
- 17:51Speaker 5: of that conversation, well, how the heck do you reconcile that? Well,
- 17:55Speaker 5: here's the point I think that's very interesting. Our brains
- 17:58Speaker 5: are lonely because they are optimized but unfulfilled. And for
- 18:03Speaker 5: the first time in human history, our brains have found
- 18:07Speaker 5: a perfect partner. And that partner is a large language model.
- 18:12Speaker 5: That's the basis for the cognitive brilliance that is a
- 18:16Speaker 5: shared dynamic or shared authorship with technology.
- 18:19Speaker 6: Yeah, you know, another key word I think you just
- 18:22Speaker 6: put in there is shared. And so one of the
- 18:24Speaker 6: things that I'd like to ask you is, so you know,
- 18:27Speaker 6: people are.
- 18:28Speaker 4: Getting familiar with their tools.
- 18:29Speaker 6: They are now out there and based on their individual
- 18:32Speaker 6: experience e there actually personally, So how how then do
- 18:37Speaker 6: we engage How should a organization And again I asked
- 18:41Speaker 6: this question not only for us as a manufacturer in
- 18:43Speaker 6: the pharmaceutical and stry but physicians down to pharmacists, how
- 18:47Speaker 6: how should we engage it so that we can fill
- 18:51Speaker 6: that opportunity in our brain that will then allow us
- 18:55Speaker 6: to think in that more expansive way. So, you know,
- 18:58Speaker 6: any thoughts on how one should start how should an
- 19:01Speaker 6: organization start incorporating AI? Is it something that we should
- 19:06Speaker 6: structure and we should bring in everybody? We should we
- 19:09Speaker 6: bring in departments and then try to bring them together
- 19:12Speaker 6: because in our industry, obviously we have a lot of
- 19:14Speaker 6: segmentation within our industry because we have manufacturing, development, you know, finance, regulatory, commercial.
- 19:21Speaker 6: How can we then, instead of being afraid of AI,
- 19:26Speaker 6: how should we think about how do we embrace it
- 19:29Speaker 6: and incorporate any thoughts.
- 19:30Speaker 5: There well, Oftentimes when my clients tell me they want
- 19:35Speaker 5: to embrace AI in their business model, my first response
- 19:38Speaker 5: is to take to advil and lead that's that's maybe
- 19:46Speaker 5: maybe not advible, but we'll have to look at the
- 19:48Speaker 5: appropriate therapeutic alignment there. But I believe that that AI
- 19:56Speaker 5: AI is not a killer app. That's one of the
- 20:00Speaker 5: big disconnects that I'm seeing. AI is not a thing
- 20:08Speaker 5: that you plug in. AI is a process with which
- 20:11Speaker 5: you engage and that is very much an experiential dynamic, okay,
- 20:16Speaker 5: And that that's something where you have to participate in
- 20:21Speaker 5: and you know, one of the best ways I get
- 20:25Speaker 5: people excited about technology is to take them for a
- 20:28Speaker 5: ride in a Tesla, put on ludicrous mode and have
- 20:33Speaker 5: it go fast, or put on you know, the full
- 20:36Speaker 5: full self driving FSD and let them go for a
- 20:39Speaker 5: ride somewhere. That that is a I think it's it's
- 20:43Speaker 5: it's pivotal, it's it's it's like a quantum shift. So
- 20:47Speaker 5: I think you have to nurture that dynamic with with
- 20:50Speaker 5: your organization because, as I said, the cognitive agent thought,
- 20:56Speaker 5: it's so fundamental to the human condition that that it
- 20:59Speaker 5: is kind of curiously different from the way we usually
- 21:02Speaker 5: do work. But I think that people have to use
- 21:05Speaker 5: it and people have to engage in this. Now here's
- 21:07Speaker 5: an interesting dynamic when we look at at the idea
- 21:12Speaker 5: of genius, at the idea of optimized cognitive function. We
- 21:15Speaker 5: often talk about it in the context of introspection, the
- 21:20Speaker 5: context of the solitary genius. We've often heard about that.
- 21:23Speaker 5: In fact, I was watching a podcast the other day
- 21:25Speaker 5: and it just kind of popped on my screen and
- 21:28Speaker 5: it said, the path to genius is one of introspection.
- 21:32Speaker 5: I don't disagree with that. I think that that to
- 21:34Speaker 5: a large degree is quite true because what that does
- 21:37Speaker 5: is it allows you to optimize the internal monologue, that's
- 21:46Speaker 5: that voice in our handle. And you've seen that with
- 21:49Speaker 5: Einstein and the thought experiments with Copernicus, with Nikola Tesla
- 21:53Speaker 5: and the way he found innovation. But I think we're
- 21:56Speaker 5: seeing the emergence of a completely new and unusual cognitive construct,
- 22:00Speaker 5: and that's the internal dialogue. The internal dialogue mediated by
- 22:05Speaker 5: your engagement with a large language model.
- 22:07Speaker 6: Yeah, so you're really talking about how you interpret yourself
- 22:10Speaker 6: internally as well as how you work.
- 22:13Speaker 5: A large language model is nothing but a mirror to
- 22:16Speaker 5: a large and that's problematic because it does kind of
- 22:19Speaker 5: feed into you in a way that is potentially dangerous.
- 22:25Speaker 5: But I still think that that that iterative dialogue that
- 22:31Speaker 5: you have is fundamental to humanity. Don't It's not new,
- 22:36Speaker 5: it's not contemporary, it's not cutting edge. It's as old
- 22:39Speaker 5: as dirt. It's Plato, it's Socrates, right, and two of
- 22:44Speaker 5: the things real quick, and I'll get off my soapbox here.
- 22:48Speaker 5: It's people sitting around the dinner table having a conversation
- 22:52Speaker 5: to advance an idea. It's kids and families sitting around
- 22:56Speaker 5: a campfire in Pennsylvania, or perhaps more interestingly, it's the
- 23:01Speaker 5: nature of cognitive engagement when physicians are on rounds. A
- 23:05Speaker 5: lot of big decisions happen on rounds when three or
- 23:08Speaker 5: four physicians are walking down the hallway discussing a patient. Well,
- 23:12Speaker 5: it's this dialogue that I think we're seeing now merge
- 23:16Speaker 5: that becomes a cognitive element of support, and I think
- 23:20Speaker 5: that's what could be a big change.
- 23:22Speaker 6: Again, I'm really tracking with you. Well, I love the
- 23:24Speaker 6: words you're using. It's really a tool to support. I
- 23:27Speaker 6: do personally resonate with what you said when it comes
- 23:31Speaker 6: to the inner talking, if you will. I see myself
- 23:34Speaker 6: do it with my photography when I've used AI and
- 23:37Speaker 6: certain elements, and I've asked myself and almost challenged myself
- 23:40Speaker 6: to think about how and why I did what I
- 23:43Speaker 6: did and what changed in the picture, what I learned
- 23:45Speaker 6: from that dynamic. You know, it even helps help me
- 23:50Speaker 6: determine how I want to use it as as a
- 23:53Speaker 6: creative tool and maintain my creative because you know, photographers
- 23:57Speaker 6: are supposed to have their thing or like any artist
- 24:00Speaker 6: have something that's their hook or hallmark. And I've found
- 24:04Speaker 6: myself thinking about it more in terms of how it
- 24:06Speaker 6: translates and let me give you an example, a very
- 24:09Speaker 6: simple example of how we've used AI so far. So recently,
- 24:13Speaker 6: we've had an executive meeting and we went out and
- 24:16Speaker 6: one of the things that we wanted to continue to
- 24:18Speaker 6: improve upon is the culture of our organization. Thinks that
- 24:23Speaker 6: we actually did is we spent some time as a
- 24:27Speaker 6: group of individuals thinking about what is kind of our
- 24:31Speaker 6: culture statement, what is it that we want to act upon,
- 24:34Speaker 6: and what do we want to make sure we communicate
- 24:36Speaker 6: to the organization.
- 24:37Speaker 4: And we did it, and we did.
- 24:40Speaker 6: A traditional paradoing and you know, we put our words
- 24:42Speaker 6: in and we bucketed them and then we've put it through.
- 24:45Speaker 4: We actually put it.
- 24:46Speaker 6: Through an AI process and it created a secondary culture statement.
- 24:54Speaker 6: And what I found with that was was it was helpful,
- 24:57Speaker 6: very helpful to all the points you're making about expansion
- 24:59Speaker 6: of thinking, taking it enhancing that dialogue and conversation. But
- 25:04Speaker 6: what I did find was that it was more kind
- 25:07Speaker 6: of back to your facts comment earlier. It kind of
- 25:10Speaker 6: put the words in order really well the things that
- 25:12Speaker 6: we're doing, but might then really catch the pure essence
- 25:17Speaker 6: what do you think about? I mean, I know that's
- 25:19Speaker 6: a simple example, but maybe one that we could translate.
- 25:22Speaker 5: No, no, no, no, no, I think I've spot on there. Look,
- 25:28Speaker 5: the fundamental truth is that AI does not think. It
- 25:32Speaker 5: doesn't think. That's why I went back to the earlier conversation,
- 25:35Speaker 5: the earlier comment about anti intelligence. Let's let's let's let's
- 25:39Speaker 5: go on, let's do a little Einstein Thode experiment here
- 25:42Speaker 5: and talk about an apple. What does an apple mean
- 25:45Speaker 5: to you and me? Well, an apple to you and
- 25:47Speaker 5: me is something that lives in three spatial dimensions, perhaps
- 25:51Speaker 5: four if you want to include time, but the three
- 25:54Speaker 5: spatial dimensions, and then it has a linguistic or semantic association.
- 25:59Speaker 5: For example, apple computer, an apple a day keeps the
- 26:03Speaker 5: doctor away. There's all sorts of things that apple is
- 26:07Speaker 5: related to, and maybe maybe there are twenty thirty forty
- 26:11Speaker 5: semantic associations. But that's the baggage. That's that's what we
- 26:14Speaker 5: have in our heads about apple. Now, when an LM
- 26:20Speaker 5: processes the word apple, and I'll avoid the technical mumbo
- 26:23Speaker 5: jumble about vectors and tokens and all that stuff, but
- 26:27Speaker 5: it looks it looks at the word in a hyperdimensional reality.
- 26:33Speaker 5: And what it looks at apple in is in the
- 26:35Speaker 5: context of twelve thousand This is for the large frontier
- 26:39Speaker 5: models twelve thousand, two hundred and eighty eight dimensions. So
- 26:44Speaker 5: just think about that, think about what that even means.
- 26:49Speaker 5: Those semantic connections are looked against the corpus of human knowledge,
- 26:54Speaker 5: and apple takes on a meaning that is nothing like
- 26:58Speaker 5: human cognitive function. In fact, what we find back in
- 27:01Speaker 5: the old days, if you want to take a cheap
- 27:03Speaker 5: shot at large language models, you'd say, oh, it just
- 27:06Speaker 5: predicts the next word, right, was the That was the
- 27:10Speaker 5: probabilistic nature of large language models. That still is true.
- 27:14Speaker 5: That's true. And what large language models do is that
- 27:19Speaker 5: they are they create a sense of linguistic cohesion. They
- 27:23Speaker 5: know what word goes with what word, and it's very
- 27:28Speaker 5: polished and it's very slick. So when you come back
- 27:29Speaker 5: with your mission statement or your analysis, it reads beautifully.
- 27:35Speaker 5: And it's that linguistic cohesion is in part cognitive theater.
- 27:42Speaker 5: You have to be very careful about that that it
- 27:45Speaker 5: doesn't think, it processes and it looks for linguistic or
- 27:50Speaker 5: semantic cohesion. So we got to be real careful about
- 27:53Speaker 5: that because because I think that large language models sometimes
- 27:57Speaker 5: are too good their model on human language. They use
- 28:01Speaker 5: dashes and semicolons and repetitive, short, choppy sentences beautifully, but
- 28:08Speaker 5: it's often a tell to what they're doing. So I
- 28:10Speaker 5: think you're on the right track. But the question here,
- 28:14Speaker 5: I think, really comes down to the nature of cognitive
- 28:18Speaker 5: offloading versus the nature of iterative intelligence. At some point,
- 28:22Speaker 5: you know, here's my phone, right, I'll share with you
- 28:26Speaker 5: that I don't know my wife's telephone, Okay, but I
- 28:30Speaker 5: don't access it. Right, I've cognitively offloaded that information because
- 28:35Speaker 5: I don't need it, I can access it. Is that
- 28:37Speaker 5: good or bad? That's a bit of a debate. But
- 28:41Speaker 5: I've also engaged the nature of my cognitive function not
- 28:44Speaker 5: as me being smart, but my ability to have an
- 28:48Speaker 5: iterative and dynamic relationship with AI. And that's the true
- 28:53Speaker 5: testament of I think what human functionality and capability is.
- 28:57Speaker 5: So it's a squirrely curious time, you know. And look,
- 29:02Speaker 5: I mean, if you're studying the crab cycle, and you know,
- 29:06Speaker 5: everybody goes to medical school or studies biology or pharmacy.
- 29:10Speaker 5: We all know Hans Krebs and ATP and all that
- 29:13Speaker 5: mumbo jumbo. And now we learned that the first intermediary
- 29:15Speaker 5: pathway was one six fructos diphosphate and we get thirty eight,
- 29:19Speaker 5: but we lose thirty two atp we lose two of
- 29:21Speaker 5: the products. Blah blah blah. Right, I'm mumbling here deliberately
- 29:25Speaker 5: because do we need to know that is? What? Do
- 29:30Speaker 5: we need to have that kind of heavy lifting? What
- 29:33Speaker 5: is the value of cognitive heavy lifting when we have
- 29:36Speaker 5: the dynamic of iterative intelligence? I'm not sure. I don't
- 29:40Speaker 5: go either way on that because I think that there
- 29:41Speaker 5: is a certain look if a patient has a cardiac
- 29:44Speaker 5: arrest and I need to, you know, establish CPR, I
- 29:48Speaker 5: need to I need to defibrillate if that's the case. Whatever,
- 29:52Speaker 5: that's something that I want to have a certain muscle memory,
- 29:54Speaker 5: sort of cognitive memory. I don't want to clutch my
- 29:57Speaker 5: phone and ask chat GPT what do I do for
- 30:00Speaker 5: ventricular fibrillation? But again, these these things are changing, and
- 30:07Speaker 5: it's it's it's very very interesting now, you know, I
- 30:09Speaker 5: want to go back. Can we go back to this
- 30:11Speaker 5: idea of of sort of workflow, sort of the nuts
- 30:14Speaker 5: and bolts of it, because I think that's important and
- 30:16Speaker 5: that's sort of the granularity of this. Will a pharmacist
- 30:21Speaker 5: become obsolete? Will a clinician become obsolete. You know, this
- 30:25Speaker 5: is a powerful question because of the idea of this
- 30:28Speaker 5: existential threat, that human obsolescence and all that stuff. But
- 30:32Speaker 5: my sense is that it will not, for reasons we
- 30:35Speaker 5: talked about with Matthew Brady and the and the and
- 30:38Speaker 5: the and you know, the photographs and all that kind
- 30:41Speaker 5: of stuff. But I think what we're seeing here is
- 30:44Speaker 5: that certainly the workflow and perhaps more importantly, the work
- 30:48Speaker 5: structure might change. So let's do a hypothetical example. Now
- 30:53Speaker 5: in medicine, let's let's look at asthma. So someone with
- 31:02Speaker 5: normal but not heightened access to care might wait a
- 31:06Speaker 5: month or two to see a pulmonologist. That's sort of
- 31:09Speaker 5: the standard of care, right it's it's for for asthma.
- 31:13Speaker 5: But I believe that what we'll see is a different
- 31:16Speaker 5: cluster of empowered people. I call it the the plus model.
- 31:20Speaker 5: So we will see a pharmacist plus, We'll see a
- 31:24Speaker 5: respiratory therapist plus, maybe a nurse plus who will be
- 31:29Speaker 5: able to manage UH spirometry data. We'll be able to
- 31:35Speaker 5: manage what what what? What you know inhaler, what steroid?
- 31:40Speaker 5: What broncho dilator? UH? This patient is on because they
- 31:44Speaker 5: will have a heightened level of function because their skill
- 31:46Speaker 5: set is augmented by artificial intelligence and technology. So what
- 31:50Speaker 5: that does is, maybe I don't need to see a
- 31:53Speaker 5: pulmonologist every month or every six months or three months.
- 31:56Speaker 5: Maybe we can lower that so that we have people
- 31:59Speaker 5: in different job structures. And what happens here, just one
- 32:03Speaker 5: quick thing is that And this is another key takeaway
- 32:08Speaker 5: with technology. Faster, better, faster, better, faster better, And that's
- 32:13Speaker 5: sort of what we think of when we think of AI. Right,
- 32:16Speaker 5: I can write that note faster, I can write a
- 32:19Speaker 5: discharge summary faster. I can look for drug drug interactions faster,
- 32:23Speaker 5: and perhaps most importantly, I can fast, I can do
- 32:26Speaker 5: that better. So faster and better is the domain of
- 32:29Speaker 5: the human engagement with AI. But I believe there's a
- 32:32Speaker 5: third leg on that stool, and we're not talking about it,
- 32:35Speaker 5: and that leg is precarious, it may not be absolute,
- 32:39Speaker 5: and it may be kind of a little little funky
- 32:41Speaker 5: these days, but I think that you enjoy the experience.
- 32:44Speaker 5: The third leg is that you enjoy the experience. So
- 32:47Speaker 5: that pharmacist with heightened clinical skill set mediated by technology,
- 32:52Speaker 5: or that respiratory therapist who can spend that extra hour
- 32:55Speaker 5: with that mom and child kind of dissecting the nuances
- 32:59Speaker 5: of asthma to optimize care is empowered.
- 33:03Speaker 6: Yeah, John, I you know, I spent a lot of
- 33:05Speaker 6: my career in asthma, so it was a great top
- 33:09Speaker 6: therapeutic are you pick?
- 33:10Speaker 5: We got lucky, we did you perfect?
- 33:14Speaker 6: So I think look at I think for me, faster
- 33:17Speaker 6: and better is kind of how we've seen the world going.
- 33:20Speaker 4: And you are right.
- 33:21Speaker 6: I think that that's how most of us interpret I
- 33:23Speaker 6: think are my organization or other organizations that we're still
- 33:26Speaker 6: thinking because that's kind of the nature, especially the pharmaceutical industry,
- 33:29Speaker 6: because it's first to first to market products and first
- 33:33Speaker 6: that's what overcomes some of the other challenges in the
- 33:35Speaker 6: construct of how our industry works. But but your point
- 33:39Speaker 6: is is AI should actually help us step back and
- 33:43Speaker 6: think and and and I agree with you. One of
- 33:46Speaker 6: the things that I'm taking away from this conversation is
- 33:49Speaker 6: that we need to change the structure. I talk a
- 33:51Speaker 6: lot about how our IP system works and how it's
- 33:54Speaker 6: not fitting to how the industry works today. I think
- 33:59Speaker 6: the pharmacist is in a great example. I think we
- 34:01Speaker 6: are going to continue to evolve and the pharmacist or
- 34:05Speaker 6: the nurse practitioner or the respiratory therapist will eventually play
- 34:10Speaker 6: a bigger role in managing asthma because the construct, the
- 34:13Speaker 6: structure that you talked about is changing. So instead of
- 34:16Speaker 6: worrying about it eliminating everything or just focusing on faster better,
- 34:23Speaker 6: maybe the way I'm going to look at AI and
- 34:26Speaker 6: tell me if this is a fair way to do
- 34:27Speaker 6: it he as an organization all the way down through
- 34:30Speaker 6: our system is let's look at how AI is going
- 34:32Speaker 6: to help with this structure of how we do things
- 34:36Speaker 6: and challenge the way we're doing it so we can
- 34:38Speaker 6: do it better. Because we think about technological advancement, which
- 34:42Speaker 6: you've talked a lot about, but we didn't really think
- 34:44Speaker 6: I didn't really put in the context more of let's
- 34:46Speaker 6: see how it changed the structural dynamic in a way
- 34:50Speaker 6: that's better. And as a result of that, and then
- 34:53Speaker 6: we put ourselves in the position to think completely both
- 34:56Speaker 6: internally and in a broader group, and then we can
- 34:58Speaker 6: take that down through the values from developing drugs all
- 35:02Speaker 6: the way down to delivering medication to the patient.
- 35:06Speaker 5: We we often look at technology and I think this
- 35:10Speaker 5: is the fault of the of the EHR, you know,
- 35:13Speaker 5: and a lot of a lot of the encumbrances that
- 35:15Speaker 5: we've we've we've experienced in medicine. We look at technology
- 35:19Speaker 5: as oppressive, as oppressive. What about if technology is liberating?
- 35:25Speaker 5: Just take a moment and think about that. Technology isn't smarter?
- 35:31Speaker 5: Technology allows you to tap the genius within remember, you know,
- 35:37Speaker 5: And this again we go down that philosophical road. We
- 35:41Speaker 5: often talk about the genius as this as the old
- 35:44Speaker 5: man sitting in in an office with the right answer
- 35:47Speaker 5: all the time. That's not the genius experience. That's the
- 35:50Speaker 5: Hollywood version of the genius experience. What we find is
- 35:53Speaker 5: the genius experience is much more related to the ah
- 35:55Speaker 5: ha moment. And that's a moment that we've all shared,
- 35:59Speaker 5: we've all experienced it. And I believe that we can
- 36:02Speaker 5: actually facilitate or kindle that cognitive dynamic through large language
- 36:08Speaker 5: models that activate that fulfill that the way to find
- 36:13Speaker 5: joy is through this cognitive stimulation.
- 36:17Speaker 6: So let me ask you again how I'm trying to
- 36:19Speaker 6: continue to think about how we engage with it. So
- 36:22Speaker 6: two questions came up. One is I always tell my
- 36:24Speaker 6: team individuals can do great things, but teams can do
- 36:28Speaker 6: exceptional things. So and that's the collective of the great
- 36:33Speaker 6: the mind of everybody.
- 36:34Speaker 4: And so.
- 36:36Speaker 6: How how should we approach using AI in that context?
- 36:41Speaker 6: Is how do we bring it to the team.
- 36:44Speaker 5: And there's a lot of a lot of theory on that.
- 36:49Speaker 5: I want to go back and just touch base on
- 36:52Speaker 5: on chain of thought reasoning, because when we talk about
- 36:56Speaker 5: workflow and we talk about you know what, what AI
- 37:00Speaker 5: does well and perhaps it doesn't do well, I'm reminded
- 37:06Speaker 5: of the story. I've told this story many times when
- 37:09Speaker 5: when a mom takes her child to the pediatrician and
- 37:13Speaker 5: then she comes home and the dad is there, or
- 37:15Speaker 5: the dad gets home from work. What's the first question?
- 37:18Speaker 5: The first question he would ask often is what did
- 37:20Speaker 5: the doctor say, Especially if it's a more urgent scenario,
- 37:24Speaker 5: such a chronic What did the doctor say, Right, well,
- 37:26Speaker 5: we're going to change that. We're going to change that,
- 37:28Speaker 5: and the question is going to be what did the
- 37:29Speaker 5: computer say. Now, that in of itself is startling. It's
- 37:35Speaker 5: based on science. It's a real thing. But the interesting
- 37:38Speaker 5: thing is that's there's a sentence there, and that's not
- 37:40Speaker 5: the end of the sentence is a comma. The end
- 37:43Speaker 5: of that and what follows is really transformative. So the
- 37:47Speaker 5: first part of the question is what did the computers say,
- 37:51Speaker 5: and the second part is what did the doctor do?
- 37:54Speaker 5: Because that human component of care is still going to
- 37:57Speaker 5: be essential.
- 37:58Speaker 4: Now.
- 37:59Speaker 5: There was a I think it was published in jam I.
- 38:01Speaker 5: It was a legit, legit paper that looked at AI
- 38:08Speaker 5: versus physicians in terms of diagnosis, and they looked at
- 38:12Speaker 5: two points. Here, they looked at the end point and
- 38:16Speaker 5: I'm going to use a heart attack as a model
- 38:18Speaker 5: because a lot of people know what a heart attack is.
- 38:20Speaker 5: Guy goes to the emergency room, sweaty, diaphoretic, looks like craps,
- 38:24Speaker 5: got chest pain. Everybody jumps to that diagnosis, right, because
- 38:28Speaker 5: that is a it's a statistical dynamic. You're probably having
- 38:31Speaker 5: a heart attack, and then and then you kind of
- 38:32Speaker 5: back out of that. Well, let's rule out this, let's
- 38:35Speaker 5: rule out that, and then we can manage you in
- 38:37Speaker 5: that context. AI and doctors kind of got it right
- 38:41Speaker 5: about seventy eight percent of the time. It's pretty good.
- 38:43Speaker 5: Same thing. But when we looked at the chain of thought,
- 38:49Speaker 5: when clinicians were asked, well, okay, so you had a
- 38:52Speaker 5: DKG with st segment elevation. What else were your options
- 38:56Speaker 5: that Did you think about an old ventricular aneurysm, did
- 38:59Speaker 5: you think about early repolarization, did you think about perry carditis?
- 39:02Speaker 5: Did you think about you know, the five other causes
- 39:04Speaker 5: of ST segment elevation. What we saw there is that
- 39:08Speaker 5: the quality of the chain of thought started to fall
- 39:12Speaker 5: down with the clinician. And what we're seeing is that
- 39:15Speaker 5: large language models and AI has a very good chain
- 39:18Speaker 5: of thought. In fact, the chain of thoughts was about
- 39:20Speaker 5: ninety three percent accurate versus about seventy eight percent accurate
- 39:24Speaker 5: for the human model. So these are partners in care.
- 39:28Speaker 4: Now.
- 39:28Speaker 5: Who managed them in the emergency room? Who it was
- 39:31Speaker 5: the clinician, it was the nurse, it was the respiratory therapist,
- 39:34Speaker 5: all those people, But I think that we have to
- 39:36Speaker 5: look at them as partners in care. Particularly the data
- 39:40Speaker 5: suggests that.
- 39:41Speaker 6: Because that care can help them implement more successfully. And
- 39:44Speaker 6: you know, one of the things that struck me when
- 39:46Speaker 6: you were saying that too is a simple thing that
- 39:48Speaker 6: we deal with all the time, from manufactured down to pharmacists,
- 39:52Speaker 6: and that is this thing called patient compliance, you know,
- 39:56Speaker 6: and I think patient compliance is not something that AI
- 39:59Speaker 6: can it's that dialogue and relationship that happens between the
- 40:03Speaker 6: provider and patient to assert that conversation. So I think
- 40:08Speaker 6: that's where we need to understand that you know where
- 40:10Speaker 6: the strength and where the limitations are. But the physician
- 40:13Speaker 6: ultimately is going to help pull through. The nurse is
- 40:15Speaker 6: going to help pull through, the pharmacist is going to
- 40:17Speaker 6: help convey those things and get a patient.
- 40:21Speaker 4: To do the thing. Me on the insight, ME, well,
- 40:24Speaker 4: you hope me. They're not perfect, but we hope that that.
- 40:27Speaker 5: But here's okay. So Sam Altman, the founder of open ai,
- 40:31Speaker 5: had a very interesting quote. He said, the most interesting
- 40:34Speaker 5: thing about a large language model is their ability to
- 40:38Speaker 5: be persuasive because of the cohesion. Remember we talked about
- 40:43Speaker 5: the apple and the language. Large language models, because they
- 40:47Speaker 5: reflect what you are saying, they often create a dialogue
- 40:51Speaker 5: that is very, very compelling. Not only is it compelling,
- 40:56Speaker 5: it's tailored to you. You know up. And there's a
- 41:00Speaker 5: couple of things I want to go over here. One
- 41:02Speaker 5: is that the way the knowledge, the way knowledge exists
- 41:05Speaker 5: in the world today is it exists in something that
- 41:07Speaker 5: I call static maps. In other words, if I want
- 41:10Speaker 5: to learn how to cook a soufle. I take that
- 41:12Speaker 5: dusty old cookbook off the shelf that says the Art
- 41:15Speaker 5: of French Cooking by Julia childlike blow the dust off.
- 41:18Speaker 5: I open up to a page and I am overwhelmed
- 41:22Speaker 5: by the technical requirements to cook this darn souflet right,
- 41:27Speaker 5: because it's her path, it's her map, it's her map.
- 41:32Speaker 5: And when I want to learn about forced expiratory volume
- 41:35Speaker 5: or ventricular fibrillation, I similarly reach off the shelf and
- 41:40Speaker 5: get Brunwall's book or somebody Harris's Principles of Internal Medicine,
- 41:44Speaker 5: and I read their journey. Now what we're seeing today
- 41:50Speaker 5: is the journey is different because if I want to
- 41:53Speaker 5: learn about how to make a souf fleg, or I
- 41:55Speaker 5: want to learn about how to manage a ventricular aneurism,
- 42:00Speaker 5: Month's status post and m I I can be trained
- 42:05Speaker 5: on that based upon my desire. Do it on my time,
- 42:09Speaker 5: do it in my language, do it in my tonality,
- 42:11Speaker 5: make it a little funny, whatever it may be. That
- 42:15Speaker 5: is knowledge that is collapsing out of the waveform, if
- 42:19Speaker 5: you will, and is being established for the first time ever,
- 42:24Speaker 5: uniquely tuned to the creative frequency of my brain.
- 42:30Speaker 4: Assembling this knowledge in a way that best fits you.
- 42:35Speaker 5: Exactly. They look, everybody knows Goodman and Gilman. Right boy,
- 42:40Speaker 5: what it's a book, It's I use it to keep
- 42:41Speaker 5: the door open, right night. Right, I mean, do you
- 42:44Speaker 5: really want to read that. It's pedantic, it's boring, it's authoritative.
- 42:48Speaker 5: It's written by some smart ass who who says this
- 42:51Speaker 5: is the way we need to understand drug drug interaction. Right,
- 42:55Speaker 5: it's it's not user friendly. In fact, what it is,
- 42:58Speaker 5: it's antithetical to something that I call learner centricity, learner censricy.
- 43:03Speaker 5: Teach me, teach me about the crab cycle, Teach me
- 43:06Speaker 5: about drug drug interactions, teach me about cytochrome P four
- 43:09Speaker 5: fifty two six. But make it fun, make it interesting.
- 43:13Speaker 5: It doesn't decrease the value. It increases the cognitive connectivity.
- 43:19Speaker 5: So that's all. That's a podcast all into itself about
- 43:22Speaker 5: medical education. Fun. But here's my point. We when we
- 43:28Speaker 5: when we hand out that script for a statin to
- 43:31Speaker 5: a patient, we give them that that that ubiquitous tear sheet,
- 43:36Speaker 5: that computer print out that says, you know, take it
- 43:39Speaker 5: every day, watch out for muscle weakness, or perhaps perhaps
- 43:43Speaker 5: antibiotics are more comic. Make sure you make sure you
- 43:46Speaker 5: take all of this, take it with not with food,
- 43:49Speaker 5: with food, whatever that may be. That's that's fine. Who's
- 43:52Speaker 5: that written for. That's a fifth grader, right, That's that's
- 43:55Speaker 5: the decree a pharma, that's the decree of American meagicine.
- 43:58Speaker 5: It's gotta be written for a fifth grade correct, which
- 44:00Speaker 5: means it's written for no one. It's written for no one.
- 44:04Speaker 5: Suppose I wanted to hand out a tearsheet that could
- 44:07Speaker 5: be crafted by an LM or a sixty five year
- 44:10Speaker 5: old engineer who might want to see a bar charge
- 44:12Speaker 5: or might even want to see a P value. Holy moly,
- 44:15Speaker 5: could you imagine doing that? Never happen? Right, So, when
- 44:18Speaker 5: you talk about convincing a patient, I think that the dialogue,
- 44:24Speaker 5: the synthetic dialogue mediated by large language models, have an
- 44:28Speaker 5: element of artificial empathy, not aiaiae. That can be a
- 44:33Speaker 5: very powerful driver that I believe personally, and drive efficacy
- 44:39Speaker 5: because we can attack compliance with a tool that's much
- 44:44Speaker 5: much better than the quick explanation you get from a
- 44:48Speaker 5: busy doctor who's got thirty seconds left before he gets
- 44:50Speaker 5: to the next patient. And there's a lot of data
- 44:53Speaker 5: on that about how AI can really be very very convincing.
- 44:57Speaker 5: So maybe there's something going on there too.
- 45:00Speaker 4: No, I agree.
- 45:01Speaker 6: I think that's very insightful. I think that our ability
- 45:04Speaker 6: to craft something that's specific for the individual so they
- 45:08Speaker 6: can interpret it or emotionally react in a way to
- 45:13Speaker 6: improve compliance or whatever it might be, is very very interesting.
- 45:17Speaker 6: So I think there's a lot of things. And you're
- 45:18Speaker 6: absolutely right. Well, I've been in the industry for over
- 45:20Speaker 6: thirty years and we've direct we craft everything we've done
- 45:24Speaker 6: promotionally not to go above a five or seventh grade.
- 45:27Speaker 5: Do you think do you think that we could even
- 45:29Speaker 5: craft five patient archetypes? Oh?
- 45:33Speaker 4: Absolutely, the busy mom.
- 45:36Speaker 5: The scientific thinker, and then three or four between, and
- 45:39Speaker 5: then make more neutral so that you can always default
- 45:41Speaker 5: to the neutrality. I just think that's so easy. And
- 45:44Speaker 5: now I think that even every patient record, every patient
- 45:48Speaker 5: when they fill out a form and they and they
- 45:50Speaker 5: include their address and their and their personal information, why
- 45:55Speaker 5: don't we do a short profile on information dissemination? How
- 46:00Speaker 5: do you like to get your information? Bunny scientific? Whatever
- 46:04Speaker 5: that becomes part of what pharmacy has to spit out
- 46:09Speaker 5: some interesting information that I believe somebody a CVS of
- 46:13Speaker 5: the world or you know, maybe a local retail is
- 46:15Speaker 5: going to do a clinical study. This is we impacted
- 46:18Speaker 5: compliance by using language.
- 46:22Speaker 4: Well, I could agree with you more.
- 46:23Speaker 6: And that's definitely a good takeaway, especially at pharmacy levels,
- 46:26Speaker 6: that we need to be able because I have a
- 46:29Speaker 6: head of our business analytics and data drives how she
- 46:33Speaker 6: thinks and reacts very different than the head of my
- 46:36Speaker 6: marketing group.
- 46:38Speaker 4: So I think that's really really fascinating.
- 46:40Speaker 5: One other point, you can make money. Do you can
- 46:45Speaker 5: differentiate your service? You know not? Let's you know, I
- 46:49Speaker 5: think it's very important that if you could create an empathic,
- 46:54Speaker 5: learner centric model. It's not patient centricity, I think is
- 46:58Speaker 5: just overrated. I mean, come on, let's face it, your pharmacy,
- 47:01Speaker 5: your retail pharmacy. Well, you may say your patient centric,
- 47:04Speaker 5: you're really chasing the dollar. That's the time you're making payroll, right,
- 47:08Speaker 5: But I think there's opportunities to leverage technology to differentiate
- 47:12Speaker 5: and drive your business. And I've been working on branding
- 47:16Speaker 5: methodologies that move beyond the conventional brand of the of
- 47:20Speaker 5: the logo and typeface and messaging into branding that lives
- 47:24Speaker 5: and comes to life through the understanding and interpretation of
- 47:28Speaker 5: a large language model because in many ways that's our
- 47:31Speaker 5: new customer because the large language model is what tells
- 47:35Speaker 5: the patient blah blah blah. Right, So really interesting dynamics.
- 47:38Speaker 6: Now, well, you know interesting in our business, we put
- 47:40Speaker 6: a big focus on the pharmacy channel.
- 47:42Speaker 4: One of the things that.
- 47:43Speaker 6: We've done with Todd, and the reason we put the
- 47:45Speaker 6: time investment to do this is is that we wanted
- 47:48Speaker 6: to listen more and understand better how we can help
- 47:52Speaker 6: them help them. And then and our goal is that
- 47:56Speaker 6: we help them, they're going to help the patient more effectively,
- 47:59Speaker 6: and if the patient's more or compliant, are better treated,
- 48:02Speaker 6: then the business side will take care of yourself to
- 48:04Speaker 6: your point, because it all comes back, you'll come back
- 48:06Speaker 6: through execute it in that way. So I know we're
- 48:09Speaker 6: coming up on our time here, but I do want
- 48:11Speaker 6: a couple of final questions. One's a very practical one
- 48:15Speaker 6: and one I've been thinking about. You know, AI has
- 48:19Speaker 6: been talked about a lot within our organization, like it
- 48:21Speaker 6: would be in any organization, whether it's in the physician's
- 48:23Speaker 6: office and the pharmacy manufacturer, whatever it might be. And
- 48:27Speaker 6: what I'm struggling a little bit with is a very
- 48:30Speaker 6: practical question that is, We've got all these different people
- 48:33Speaker 6: that are starting to touch it, and.
- 48:37Speaker 4: My concern is.
- 48:38Speaker 6: That how do we uh embrace it in a way
- 48:41Speaker 6: as an organization to actually make it work for us?
- 48:44Speaker 6: So is this, you know, is a really supposed to
- 48:46Speaker 6: be led from the executive suite down to through the organization,
- 48:50Speaker 6: because like in many organizations I've talked to, it's the
- 48:53Speaker 6: the it people, it's the tech people that are bringing
- 48:56Speaker 6: it in, and I think that's like the worst place
- 48:59Speaker 6: for it to start. But I also don't want one
- 49:02Speaker 6: group to embrace it this way and that way and
- 49:04Speaker 6: that way, and then how are we then bringing it
- 49:06Speaker 6: in a cohesive way together to actually produce some of
- 49:09Speaker 6: the outcome that you've been talking about. So, if you
- 49:12Speaker 6: to offer any advice to an organization, whether it be
- 49:15Speaker 6: a manufacturer or even a pharmacist running their independent pharmacy
- 49:18Speaker 6: and they have multiple touch points, how would you go
- 49:22Speaker 6: approach really bringing in a way that could produce the
- 49:26Speaker 6: output that you've been talking about today.
- 49:28Speaker 5: That's our next That's the whole topic for our next podcast,
- 49:31Speaker 5: right because that I can go on and on on,
- 49:33Speaker 5: but I think there are a few a few interesting
- 49:35Speaker 5: points there, you know, it's easy to say that it's top,
- 49:38Speaker 5: top down or bottom up. I think that that culture
- 49:41Speaker 5: squashes innovation. That people have to understand that that bottom
- 49:46Speaker 5: up is a good a way to do this. Number one.
- 49:48Speaker 5: Number two, you have to recognize that there is no
- 49:50Speaker 5: killer app. This is not about functionality. This is about
- 49:54Speaker 5: the cognitive construct that changes changes thing completely. The third
- 50:01Speaker 5: is that we can't look at this as a single
- 50:02Speaker 5: adoption curve. A lot of people, a lot of companies
- 50:05Speaker 5: make a mistake and say, let's measure adoption of this.
- 50:10Speaker 5: It's wrong. In fact, there are probably two, if not
- 50:12Speaker 5: three adoption curves, and we have to be mindful of that.
- 50:15Speaker 5: There's the logistics. There's the sort of the mechanistic underpinnings
- 50:20Speaker 5: of AI to manage functionality. That year on year is
- 50:26Speaker 5: up sixty eight per sixty eight or seventy percent. In
- 50:29Speaker 5: clinical settings, people are using it more and more. You
- 50:32Speaker 5: want to schedule, you want to do logistic things, that's
- 50:35Speaker 5: the place to go and people are comfortable with that.
- 50:37Speaker 5: The other one is the clinical or cognitive side, and
- 50:39Speaker 5: that actually went down one percent year on year last
- 50:42Speaker 5: year because I think clinicians are are a little reluctant.
- 50:47Speaker 5: Remember if you're in the hospital, you're in the office,
- 50:49Speaker 5: who's the smartest person in the room. It's the doctor.
- 50:52Speaker 5: We know that that's the answer you have to give.
- 50:54Speaker 5: The reality is no longer true. It's the computer that's
- 50:57Speaker 5: the smartest person in the room. Play some head games.
- 51:01Speaker 5: So I think that from the respective of adoption and
- 51:04Speaker 5: adapting this technology, we have to look at it in
- 51:07Speaker 5: terms of its use cases, and they're different ones. But
- 51:11Speaker 5: I think the data is becoming very very clear that
- 51:16Speaker 5: the ability of AI to find patterns, to come up
- 51:19Speaker 5: with differential diagnoses, really to become an integral part of
- 51:24Speaker 5: care is here without a doubt. And I think the
- 51:26Speaker 5: takeaway is that that AI is no longer an option,
- 51:29Speaker 5: it's an imperative.
- 51:30Speaker 6: Yeah, And I will close on this from a medical standpoint.
- 51:34Speaker 6: You know, one of the things that we've always done
- 51:36Speaker 6: is organizations is you know, we take asthma, right, we
- 51:39Speaker 6: kind of use this label asthma, but there's so many
- 51:42Speaker 6: subpopulations of patients in the asthma, whether they're moving on
- 51:47Speaker 6: to have COPD, whether or not they've got other comorbilities,
- 51:51Speaker 6: and we need to find more sophisticated ways of making
- 51:54Speaker 6: sure that the right treatment regimen actually fits those subpopulations better.
- 51:59Speaker 4: And I think that's what you know.
- 52:01Speaker 5: It's not only better treatment regiments. So it's not necessarily
- 52:06Speaker 5: a better LAVA long acting bronco dilator. Maybe it's a
- 52:11Speaker 5: better cognitive alignment to understand the best way to take
- 52:14Speaker 5: care of yourself every patient scenario. The labeling restricts us.
- 52:19Speaker 5: You know, the one problem. The nice thing about continuous
- 52:21Speaker 5: blood glucose monitoring is I can tweak insulin. I can
- 52:24Speaker 5: tweak that insulin up and down to get really tight control.
- 52:27Speaker 5: There's no other drug I can do that, right, I've
- 52:30Speaker 5: got fixed dose, and fixed dose is mediated by the
- 52:34Speaker 5: label to a large degree. So I struggle with that.
- 52:37Speaker 5: But I think that if we can align asthma, I mean, boy, asthma, temperature, key,
- 52:43Speaker 5: pollen dander, inner city country, there's so many parameters that
- 52:48Speaker 5: can be uniquely fine tuned, and I think that's going
- 52:51Speaker 5: to be partly the burden on the patient and the caregiver, Yeah,
- 52:54Speaker 5: to kind of understand.
- 52:55Speaker 6: That, because that's where we're going to create a greater
- 52:57Speaker 6: connection with the patient to take more ownership what they're doing.
- 53:00Speaker 6: So ultimately, this whole cycle care from development of drugs
- 53:05Speaker 6: to the diagnosis, to the treatment, to the management, to
- 53:08Speaker 6: the interaction. I think we'll get better and I really
- 53:10Speaker 6: think that's fantastic. Well, I think after this podcast ends,
- 53:13Speaker 6: I'm going to be talking to Todd John, because I
- 53:15Speaker 6: think we might need to have a special carve out
- 53:18Speaker 6: with a couple of follow up ais, if your discussions,
- 53:21Speaker 6: If you're to it, this is what the Executive Dose
- 53:25Speaker 6: podcast was really meant to be, is to open up
- 53:29Speaker 6: the dialogue from manufacture to pharmacists and make sure that
- 53:34Speaker 6: we're all having the opportunity to work more comprehensively and
- 53:38Speaker 6: cohesively together in a way to create better outcome. And
- 53:42Speaker 6: I think that this podcast kind of did that in spade.
- 53:46Speaker 6: So John can't thank you enough for your hugasm and
- 53:51Speaker 6: your intellect and your insight and your knowledge, and we
- 53:54Speaker 6: look forward to having you come back again here real soon.
- 53:56Speaker 6: If you're open to it, you bet